Fatigue clinical trials

Explore recruiting fatigue clinical trials.

Recruiting fatigue studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fatigue trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Thiamine against chronic rheumatoid arthritis fatigue

Denmark

Phase II and Phase III (Integrated) EU CTIS Study details

PDH-RAVICTI - A PHASE II, MULTICENTRIC, PROSPECTIVE, NON-COMPARATIVE CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF THE TREATMENT OF PYRUVATE DEHYDROGENASE DEFICIENCY (PDH) PATIENTS WITH GLYCEROL PHENYLBUTYRATE (RAVICTI®)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

The effects of the manipulation of 5-HT, DA and NA on exercise-induced fatigue and brain activation

Belgium

Phase III and phase IV (Integrated) EU CTIS Study details

BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

EFFICACY AND SAFETY OF CROMOGLYCATE AS A NEW SYMPTOMATIC TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Fatigue trials by city

Fatigue in Toronto Fatigue in Vancouver Fatigue in Montreal Fatigue in Calgary Fatigue in Edmonton Fatigue in Ottawa Fatigue in Winnipeg Fatigue in Quebec City Fatigue in Hamilton Fatigue in Kitchener Fatigue in London Fatigue in Halifax Fatigue in New York Fatigue in Los Angeles Fatigue in Chicago Fatigue in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease